Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

CD68 Market by Type (Above 90%, Above 95%, Above 99%, Others) and by Application (Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A14022

Pages: NA

Charts: NA

Tables: NA

CD68, also known as macrosialin in mice, is a member class D scavenger receptors. It is a glycosylated type I membrane protein, which is expressed in mononuclear phagocytes and other macrophages. CD68 is transcendently communicated in endosomes and lysosomes of macrophages and found on the outside of DCs and osteoclasts. CD68 has been broadly utilized as a pan-macrophage marker. High thickness of CD68+ TAMs is associated with high stromal and serum levels of VEGF. Regulation of VEGF in macrophages by IR is known to diminish the antitumor viability of radiotherapy. Additionally, CD68 is widely used as an indicator for malignancy forecast.

COVID-19 Impact Analysis

  • Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global CD68 market.

Top Impacting Factors
Increase in research and development centers for development of disease prevention mechanisms and diabetic therapeutic medications coupled with rising awareness on CD68 and presence of higher population base in India and China are anticipated to drive market growth.

Additionally, favorable reimbursement policies coupled with supportive regulatory norms in countries such as India and Singapore are further anticipated to drive market growth.

However, stringent regulations in fragile economies such as Cuba and Vietnam coupled with low per capita income is anticipated to hamper market growth in these regions.

Additionally, higher costs associated with laboratory research pertaining to CD68 may further hamper market growth of CD68 market.

Key Market Trends

  • North America is anticipated to dominate the market, owing to rising number of chronic diseases in the region coupled with growing underlying demand for advanced therapeutic medications and rise in government spending in biotechnology research and development.
  • Europe exhibits huge growth potential for CD68 due to prevalence of tumors and bosom malignancy in the region coupled with presence of highly industrialized economies in the region, which benefit from the higher disposable incomes.
  • Asia-Pacific is anticipated to witness exponential growth, owing to improving medical care foundation, bringing down administrative obstacles, and expanding research and development ventures in the region.
  • Latin American is anticipated to witness constant growth, owing to  rise in government spending in the medical services industry coupled with rise in awareness of biotechnology and associated fields.
  •  
  • Middle East and Africa are expected witness stagnant growth, due to lack of research and development facilities in the region, lack of medical infrastructure coupled with fragile legal and economic condition, and less awareness on biotechnology.

Key Benefits of the Report

  • This study presents the analytical depiction of the CD68 industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the CD68 Market share.
  • The current market is quantitatively analyzed to highlight market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the CD68 Market Report

  • Which are the leading players active in the CD68 market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the CD68 market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is CD68 market?
  • What is the CD68 market prediction in the future?
  • What are the current trends and predicted trends?
     

 Key Market Segments

  • By Type
    • Above 90%
    • Above 95%
    • Above 99%
    • Others
  • By Application
    • Biopharmaceutical Companies
    • Hospitals
    • Bioscience Research Institutions
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

 
Key Market Players

  • ProSci
  • Novus Biologicals
  • BioLegend
  • Genetex
  • Abiocode
  • Biobyt
  • BethylLaboratories
  • St John's Laboratory Ltd.
  • ProteoGenix
  • RandD Systems
  • Atlas Antibodies
  • Bio-Rad
  • Biosensis
  • Boster Biological Technology
  • Proteintech
  • Abbexa Ltd
  • Epigentek,
  • Bioss Antibodies
  • Aviva Systems Biology Corporation
  • Stemcell
  • Lifespan Biosciences
  • EnzoLifeSciences
  • Rockland
  • BioVision

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: CD68 MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Above 90%

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Above 95%

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Above 99%

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: CD68 MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Biopharmaceutical Companies

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Hospitals

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Bioscience Research Institutions

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: CD68 MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Cd68 Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Cd68 Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Cd68 Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Cd68 Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Cd68 Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Cd68 Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Cd68 Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Cd68 Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Cd68 Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Cd68 Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Cd68 Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Cd68 Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Cd68 Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Cd68 Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Cd68 Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Cd68 Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Cd68 Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Cd68 Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Cd68 Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Cd68 Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Cd68 Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Cd68 Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Cd68 Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Cd68 Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Cd68 Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Aviva Systems Biology Corporation

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Atlas Antibodies

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Abbexa Ltd

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Abiocode

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Boster Biological Technology

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Biobyt

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Bio-Rad

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Bioss Antibodies

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Biosensis

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. BioLegend

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

    • 8.11. BioVision

      • 8.11.1. Company Overview

      • 8.11.2. Key Executives

      • 8.11.3. Company Snapshot

      • 8.11.4. Operating Business Segments

      • 8.11.5. Product Portfolio

      • 8.11.6. Business Performance

      • 8.11.7. Key Strategic Moves and Developments

    • 8.12. BethylLaboratories

      • 8.12.1. Company Overview

      • 8.12.2. Key Executives

      • 8.12.3. Company Snapshot

      • 8.12.4. Operating Business Segments

      • 8.12.5. Product Portfolio

      • 8.12.6. Business Performance

      • 8.12.7. Key Strategic Moves and Developments

    • 8.13. Epigentek,

      • 8.13.1. Company Overview

      • 8.13.2. Key Executives

      • 8.13.3. Company Snapshot

      • 8.13.4. Operating Business Segments

      • 8.13.5. Product Portfolio

      • 8.13.6. Business Performance

      • 8.13.7. Key Strategic Moves and Developments

    • 8.14. EnzoLifeSciences

      • 8.14.1. Company Overview

      • 8.14.2. Key Executives

      • 8.14.3. Company Snapshot

      • 8.14.4. Operating Business Segments

      • 8.14.5. Product Portfolio

      • 8.14.6. Business Performance

      • 8.14.7. Key Strategic Moves and Developments

    • 8.15. Genetex

      • 8.15.1. Company Overview

      • 8.15.2. Key Executives

      • 8.15.3. Company Snapshot

      • 8.15.4. Operating Business Segments

      • 8.15.5. Product Portfolio

      • 8.15.6. Business Performance

      • 8.15.7. Key Strategic Moves and Developments

    • 8.16. Lifespan Biosciences

      • 8.16.1. Company Overview

      • 8.16.2. Key Executives

      • 8.16.3. Company Snapshot

      • 8.16.4. Operating Business Segments

      • 8.16.5. Product Portfolio

      • 8.16.6. Business Performance

      • 8.16.7. Key Strategic Moves and Developments

    • 8.17. Novus Biologicals

      • 8.17.1. Company Overview

      • 8.17.2. Key Executives

      • 8.17.3. Company Snapshot

      • 8.17.4. Operating Business Segments

      • 8.17.5. Product Portfolio

      • 8.17.6. Business Performance

      • 8.17.7. Key Strategic Moves and Developments

    • 8.18. Proteintech

      • 8.18.1. Company Overview

      • 8.18.2. Key Executives

      • 8.18.3. Company Snapshot

      • 8.18.4. Operating Business Segments

      • 8.18.5. Product Portfolio

      • 8.18.6. Business Performance

      • 8.18.7. Key Strategic Moves and Developments

    • 8.19. ProSci

      • 8.19.1. Company Overview

      • 8.19.2. Key Executives

      • 8.19.3. Company Snapshot

      • 8.19.4. Operating Business Segments

      • 8.19.5. Product Portfolio

      • 8.19.6. Business Performance

      • 8.19.7. Key Strategic Moves and Developments

    • 8.20. ProteoGenix

      • 8.20.1. Company Overview

      • 8.20.2. Key Executives

      • 8.20.3. Company Snapshot

      • 8.20.4. Operating Business Segments

      • 8.20.5. Product Portfolio

      • 8.20.6. Business Performance

      • 8.20.7. Key Strategic Moves and Developments

    • 8.21. RandD Systems

      • 8.21.1. Company Overview

      • 8.21.2. Key Executives

      • 8.21.3. Company Snapshot

      • 8.21.4. Operating Business Segments

      • 8.21.5. Product Portfolio

      • 8.21.6. Business Performance

      • 8.21.7. Key Strategic Moves and Developments

    • 8.22. Rockland

      • 8.22.1. Company Overview

      • 8.22.2. Key Executives

      • 8.22.3. Company Snapshot

      • 8.22.4. Operating Business Segments

      • 8.22.5. Product Portfolio

      • 8.22.6. Business Performance

      • 8.22.7. Key Strategic Moves and Developments

    • 8.23. St John's Laboratory Ltd.

      • 8.23.1. Company Overview

      • 8.23.2. Key Executives

      • 8.23.3. Company Snapshot

      • 8.23.4. Operating Business Segments

      • 8.23.5. Product Portfolio

      • 8.23.6. Business Performance

      • 8.23.7. Key Strategic Moves and Developments

    • 8.24. Stemcell

      • 8.24.1. Company Overview

      • 8.24.2. Key Executives

      • 8.24.3. Company Snapshot

      • 8.24.4. Operating Business Segments

      • 8.24.5. Product Portfolio

      • 8.24.6. Business Performance

      • 8.24.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CD68 MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL CD68 MARKET FOR ABOVE 90%, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL CD68 MARKET FOR ABOVE 95%, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL CD68 MARKET FOR ABOVE 99%, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL CD68 MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL CD68 MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL CD68 MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL CD68 MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL CD68 MARKET FOR BIOSCIENCE RESEARCH INSTITUTIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL CD68 MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL CD68 MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA CD68, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 15. U.S. CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 16. U.S. CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 17. CANADA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. CANADA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE CD68, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. ITALY CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 29. ITALY CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. UK CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. UK CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC CD68, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. CHINA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. CHINA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. INDIA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. INDIA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA CD68, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. UAE CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. UAE CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA CD68, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA CD68, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 74. AVIVA SYSTEMS BIOLOGY CORPORATION: KEY EXECUTIVES
  • TABLE 75. AVIVA SYSTEMS BIOLOGY CORPORATION: COMPANY SNAPSHOT
  • TABLE 76. AVIVA SYSTEMS BIOLOGY CORPORATION: OPERATING SEGMENTS
  • TABLE 77. AVIVA SYSTEMS BIOLOGY CORPORATION: PRODUCT PORTFOLIO
  • TABLE 78. AVIVA SYSTEMS BIOLOGY CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. ATLAS ANTIBODIES: KEY EXECUTIVES
  • TABLE 80. ATLAS ANTIBODIES: COMPANY SNAPSHOT
  • TABLE 81. ATLAS ANTIBODIES: OPERATING SEGMENTS
  • TABLE 82. ATLAS ANTIBODIES: PRODUCT PORTFOLIO
  • TABLE 83. ATLAS ANTIBODIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. ABBEXA LTD: KEY EXECUTIVES
  • TABLE 85. ABBEXA LTD: COMPANY SNAPSHOT
  • TABLE 86. ABBEXA LTD: OPERATING SEGMENTS
  • TABLE 87. ABBEXA LTD: PRODUCT PORTFOLIO
  • TABLE 88. ABBEXA LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. ABIOCODE: KEY EXECUTIVES
  • TABLE 90. ABIOCODE: COMPANY SNAPSHOT
  • TABLE 91. ABIOCODE: OPERATING SEGMENTS
  • TABLE 92. ABIOCODE: PRODUCT PORTFOLIO
  • TABLE 93. ABIOCODE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. BOSTER BIOLOGICAL TECHNOLOGY: KEY EXECUTIVES
  • TABLE 95. BOSTER BIOLOGICAL TECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 96. BOSTER BIOLOGICAL TECHNOLOGY: OPERATING SEGMENTS
  • TABLE 97. BOSTER BIOLOGICAL TECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 98. BOSTER BIOLOGICAL TECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. BIOBYT: KEY EXECUTIVES
  • TABLE 100. BIOBYT: COMPANY SNAPSHOT
  • TABLE 101. BIOBYT: OPERATING SEGMENTS
  • TABLE 102. BIOBYT: PRODUCT PORTFOLIO
  • TABLE 103. BIOBYT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. BIO-RAD: KEY EXECUTIVES
  • TABLE 105. BIO-RAD: COMPANY SNAPSHOT
  • TABLE 106. BIO-RAD: OPERATING SEGMENTS
  • TABLE 107. BIO-RAD: PRODUCT PORTFOLIO
  • TABLE 108. BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. BIOSS ANTIBODIES: KEY EXECUTIVES
  • TABLE 110. BIOSS ANTIBODIES: COMPANY SNAPSHOT
  • TABLE 111. BIOSS ANTIBODIES: OPERATING SEGMENTS
  • TABLE 112. BIOSS ANTIBODIES: PRODUCT PORTFOLIO
  • TABLE 113. BIOSS ANTIBODIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. BIOSENSIS: KEY EXECUTIVES
  • TABLE 115. BIOSENSIS: COMPANY SNAPSHOT
  • TABLE 116. BIOSENSIS: OPERATING SEGMENTS
  • TABLE 117. BIOSENSIS: PRODUCT PORTFOLIO
  • TABLE 118. BIOSENSIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. BIOLEGEND: KEY EXECUTIVES
  • TABLE 120. BIOLEGEND: COMPANY SNAPSHOT
  • TABLE 121. BIOLEGEND: OPERATING SEGMENTS
  • TABLE 122. BIOLEGEND: PRODUCT PORTFOLIO
  • TABLE 123. BIOLEGEND: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. BIOVISION: KEY EXECUTIVES
  • TABLE 125. BIOVISION: COMPANY SNAPSHOT
  • TABLE 126. BIOVISION: OPERATING SEGMENTS
  • TABLE 127. BIOVISION: PRODUCT PORTFOLIO
  • TABLE 128. BIOVISION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129. BETHYLLABORATORIES: KEY EXECUTIVES
  • TABLE 130. BETHYLLABORATORIES: COMPANY SNAPSHOT
  • TABLE 131. BETHYLLABORATORIES: OPERATING SEGMENTS
  • TABLE 132. BETHYLLABORATORIES: PRODUCT PORTFOLIO
  • TABLE 133. BETHYLLABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 134. EPIGENTEK,: KEY EXECUTIVES
  • TABLE 135. EPIGENTEK,: COMPANY SNAPSHOT
  • TABLE 136. EPIGENTEK,: OPERATING SEGMENTS
  • TABLE 137. EPIGENTEK,: PRODUCT PORTFOLIO
  • TABLE 138. EPIGENTEK,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 139. ENZOLIFESCIENCES: KEY EXECUTIVES
  • TABLE 140. ENZOLIFESCIENCES: COMPANY SNAPSHOT
  • TABLE 141. ENZOLIFESCIENCES: OPERATING SEGMENTS
  • TABLE 142. ENZOLIFESCIENCES: PRODUCT PORTFOLIO
  • TABLE 143. ENZOLIFESCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 144. GENETEX: KEY EXECUTIVES
  • TABLE 145. GENETEX: COMPANY SNAPSHOT
  • TABLE 146. GENETEX: OPERATING SEGMENTS
  • TABLE 147. GENETEX: PRODUCT PORTFOLIO
  • TABLE 148. GENETEX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149. LIFESPAN BIOSCIENCES: KEY EXECUTIVES
  • TABLE 150. LIFESPAN BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 151. LIFESPAN BIOSCIENCES: OPERATING SEGMENTS
  • TABLE 152. LIFESPAN BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 153. LIFESPAN BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 154. NOVUS BIOLOGICALS: KEY EXECUTIVES
  • TABLE 155. NOVUS BIOLOGICALS: COMPANY SNAPSHOT
  • TABLE 156. NOVUS BIOLOGICALS: OPERATING SEGMENTS
  • TABLE 157. NOVUS BIOLOGICALS: PRODUCT PORTFOLIO
  • TABLE 158. NOVUS BIOLOGICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 159. PROTEINTECH: KEY EXECUTIVES
  • TABLE 160. PROTEINTECH: COMPANY SNAPSHOT
  • TABLE 161. PROTEINTECH: OPERATING SEGMENTS
  • TABLE 162. PROTEINTECH: PRODUCT PORTFOLIO
  • TABLE 163. PROTEINTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 164. PROSCI: KEY EXECUTIVES
  • TABLE 165. PROSCI: COMPANY SNAPSHOT
  • TABLE 166. PROSCI: OPERATING SEGMENTS
  • TABLE 167. PROSCI: PRODUCT PORTFOLIO
  • TABLE 168. PROSCI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 169. PROTEOGENIX: KEY EXECUTIVES
  • TABLE 170. PROTEOGENIX: COMPANY SNAPSHOT
  • TABLE 171. PROTEOGENIX: OPERATING SEGMENTS
  • TABLE 172. PROTEOGENIX: PRODUCT PORTFOLIO
  • TABLE 173. PROTEOGENIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 174. RANDD SYSTEMS: KEY EXECUTIVES
  • TABLE 175. RANDD SYSTEMS: COMPANY SNAPSHOT
  • TABLE 176. RANDD SYSTEMS: OPERATING SEGMENTS
  • TABLE 177. RANDD SYSTEMS: PRODUCT PORTFOLIO
  • TABLE 178. RANDD SYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 179. ROCKLAND: KEY EXECUTIVES
  • TABLE 180. ROCKLAND: COMPANY SNAPSHOT
  • TABLE 181. ROCKLAND: OPERATING SEGMENTS
  • TABLE 182. ROCKLAND: PRODUCT PORTFOLIO
  • TABLE 183. ROCKLAND: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 184. ST JOHN'S LABORATORY LTD.: KEY EXECUTIVES
  • TABLE 185. ST JOHN'S LABORATORY LTD.: COMPANY SNAPSHOT
  • TABLE 186. ST JOHN'S LABORATORY LTD.: OPERATING SEGMENTS
  • TABLE 187. ST JOHN'S LABORATORY LTD.: PRODUCT PORTFOLIO
  • TABLE 188. ST JOHN'S LABORATORY LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 189. STEMCELL: KEY EXECUTIVES
  • TABLE 190. STEMCELL: COMPANY SNAPSHOT
  • TABLE 191. STEMCELL: OPERATING SEGMENTS
  • TABLE 192. STEMCELL: PRODUCT PORTFOLIO
  • TABLE 193. STEMCELL: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CD68 MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CD68 MARKET
  • FIGURE 3. SEGMENTATION CD68 MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CD68 MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCD68 MARKET
  • FIGURE 11. CD68 MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. CD68 MARKET FOR ABOVE 90%, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. CD68 MARKET FOR ABOVE 95%, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. CD68 MARKET FOR ABOVE 99%, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. CD68 MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. CD68 MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 17. CD68 MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. CD68 MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. CD68 MARKET FOR BIOSCIENCE RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. CD68 MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: CD68 MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. AVIVA SYSTEMS BIOLOGY CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. AVIVA SYSTEMS BIOLOGY CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. AVIVA SYSTEMS BIOLOGY CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. ATLAS ANTIBODIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. ATLAS ANTIBODIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. ATLAS ANTIBODIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. ABBEXA LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. ABBEXA LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. ABBEXA LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. ABIOCODE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. ABIOCODE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. ABIOCODE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. BOSTER BIOLOGICAL TECHNOLOGY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. BOSTER BIOLOGICAL TECHNOLOGY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. BOSTER BIOLOGICAL TECHNOLOGY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. BIOBYT: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. BIOBYT: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. BIOBYT: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. BIO-RAD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. BIO-RAD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. BIO-RAD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. BIOSS ANTIBODIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. BIOSS ANTIBODIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. BIOSS ANTIBODIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. BIOSENSIS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. BIOSENSIS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. BIOSENSIS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. BIOLEGEND: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. BIOLEGEND: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. BIOLEGEND: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. BIOVISION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. BIOVISION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. BIOVISION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 61. BETHYLLABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 62. BETHYLLABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 63. BETHYLLABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 64. EPIGENTEK,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 65. EPIGENTEK,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 66. EPIGENTEK,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 67. ENZOLIFESCIENCES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 68. ENZOLIFESCIENCES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 69. ENZOLIFESCIENCES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 70. GENETEX: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 71. GENETEX: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 72. GENETEX: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 73. LIFESPAN BIOSCIENCES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 74. LIFESPAN BIOSCIENCES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 75. LIFESPAN BIOSCIENCES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 76. NOVUS BIOLOGICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 77. NOVUS BIOLOGICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 78. NOVUS BIOLOGICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 79. PROTEINTECH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 80. PROTEINTECH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 81. PROTEINTECH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 82. PROSCI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 83. PROSCI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 84. PROSCI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 85. PROTEOGENIX: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 86. PROTEOGENIX: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 87. PROTEOGENIX: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 88. RANDD SYSTEMS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 89. RANDD SYSTEMS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 90. RANDD SYSTEMS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 91. ROCKLAND: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 92. ROCKLAND: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 93. ROCKLAND: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 94. ST JOHN'S LABORATORY LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 95. ST JOHN'S LABORATORY LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 96. ST JOHN'S LABORATORY LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 97. STEMCELL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 98. STEMCELL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 99. STEMCELL: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
CD68 Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved